|
Next-generation sequencing (NGS) identifies a new breast cancer subtype with HER2 low-amplification status as a candidate for targeted therapy. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Burning Rock Biotech |
Honoraria - Burning Rock Biotech |
Travel, Accommodations, Expenses - Burning Rock Biotech |
|
|
Employment - Analyn Lizaso |
Honoraria - Analyn Lizaso |
Travel, Accommodations, Expenses - Analyn Lizaso |
|
|
Employment - Han Han-Zhang |
Honoraria - Han Han-Zhang |
Travel, Accommodations, Expenses - Han Han-Zhang |
|
|
Employment - Burning Rock Biotech |
Leadership - Burning Rock Biotech |
Honoraria - Burning Rock Biotech |
Travel, Accommodations, Expenses - Burning Rock Biotech |
|
|
No Relationships to Disclose |
|
|
Employment - Burning Rock Biotech |
Honoraria - Burning Rock Biotech |
Travel, Accommodations, Expenses - Burning Rock Biotech |
|
|
|
|
Travel, Accommodations, Expenses - Zhou Zhang |